Leading R&D teams are already leveraging digital chemistry to outpace the competition. Yet, traditional quantum and force field simulations are stuck in a 'speed vs. accuracy' trade-off. At our next webinar, we reveal how Schrödinger’s Machine Learning Force Fields (MLFFs) are breaking the cycle. Discover how to achieve DFT-level accuracy at the massive scales required for real-world battery innovation—from complex electrolyte formulations to cathode coatings. Don't let computational bottlenecks slow down your discovery. Register now: https://hubs.li/Q0487XLw0
Schrödinger
Software Development
New York, New York 64,185 followers
Transforming drug discovery and materials research
About us
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990 and is engaged with customers and collaborators in more than 70 countries. We welcome you to visit our blog at www.extrapolations.com. Stay Alert: Avoid Recruitment Scams Across industries, cybercriminals are posing as company recruiters using fake job postings and employment offers. Please stay vigilant: - Never provide personal/financial information or payment to anyone claiming to offer a job opportunity - Always verify job postings through official company websites or direct contacts - Be cautious of unusual communication methods or overly quick offers
- Website
-
http://www.schrodinger.com
External link for Schrödinger
- Industry
- Software Development
- Company size
- 501-1,000 employees
- Headquarters
- New York, New York
- Type
- Public Company
- Founded
- 1990
Locations
Employees at Schrödinger
Updates
-
Schrödinger is excited to be back at this year’s In-Cosmetics Global in Paris! Join us to explore how cutting-edge computational science is transforming cosmetics R&D. On April 14th, Schrödinger’s Jeffrey Sanders will share how combining physics-based simulations with AI enables more accurate ingredient characterization and accelerates the development of high-performance, sustainable formulations. Visit us at booth 1A100 to connect with our team. Learn more: https://hubs.li/Q0485lgg0 #Schrödinger #MaterialsScience #Sustainability #AI#DigitalChemistry #Cosmetics #InCosmeticsGlobal
-
-
The high-stakes race of antibody discovery is often won or lost in the "information gap" between raw experimental data and critical structural insights. Stop losing critical time in this gap. In our upcoming webinar, we’ll demonstrate how to unite in silico predictions with your experimental data for more informed candidate selection. You will see how LiveDesign for Biologics is enabling bench scientists to visualize 3D complexes and predict developability parameters – and be able to ask questions to understand how the platform and tools can improve your antibody discovery workflows. Register today: https://hubs.li/Q0487Sps0
-
-
"When I solved the Schrödinger equation for myself, I understood how it worked, what it meant, and I began to look at the world differently." For Art Bochevarov, Research Leader at Schrödinger, the equation is more than a calculation, it is a shift in perspective. While it serves as the foundation for our understanding of chemistry, it also introduces us to the most enigmatic corners of our universe, from the role of the observer to the nature of the wave function. As we celebrate 100 years of the Schrödinger Equation (1926–2026), we look to its unshakable reputation as the standard we aspire to every day. #Schrodinger100Years
-
Reflecting on a standout morning from a couple of weeks ago when we hosted the 2026 New York Tiger Trek cohort at our Manhattan headquarters! It was an absolute pleasure to welcome 17 of Princeton University’s student leaders for an immersive look at how software is revolutionizing the life sciences. From a deep dive with Abba Leffler to a dynamic dialogue on our "predict-first" discovery paradigm, the energy and curiosity in the room were truly inspiring. One of the visiting students shared their reflections on the session in a fantastic article, and we’re proud to highlight their perspective on how leadership and scientific rigor can coexist at scale. Read the student’s full recap of the visit here: https://hubs.li/Q048b69B0 A big thanks to the #NYTT cohort for the fresh perspectives and the thoughtful questions that are still sparking conversations among our team. #Schrödinger #PrincetonUniversity #NYTT2026 #FutureOfScience #StudentLeadership #Innovation #LifeSciences
-
-
We are thrilled to be at NERDG 2026 in Groton, CT on March 30th! As drug development becomes increasingly complex, the ability to predict degradation, solubility, and stability before hitting the wet lab is a game-changer. Our team is bridging the gap between molecular discovery and the final drug product. Join us for a presentation on predictive modeling in drug formulation and stop by booth #2 to speak with Schrödinger scientists. Learn more: https://hubs.li/Q047YqQP0
-
-
We’re excited to be at SOT 2026! This year, we are showcasing our Predictive Toxicology capabilities as part of the Computational Toxicology and Drug Discovery specialty sections. We’ll demonstrate how physics-based FEP methods can predict both off-target binding affinity (Kd) and atomistic holo-complex structures – allowing researchers to rationally design out toxicities while maintaining primary efficacy. Stop by our posters to see how Schrödinger is bringing a new level of predictive power to off-target de-risking. #2026SOT #ToxExpo #Toxicology #DrugDiscovery #FEP
-
The discovery of zasocitinib, an investigational TYK2 inhibitor, is a masterclass in collaboration and perseverance between the scientists at Nimbus and Schrödinger. Now being advanced by Takeda, this highly selective inhibitor represents a potential leap forward for patients living with #psoriasis and #PsoriaticArthritis. We are thrilled to see Takeda driving the science forward to address the significant needs in inflammatory disease. Read our original blog post: https://lnkd.in/eiQrAtTS Watch the update from Takeda below to explore the TYK2 mechanism of action.
Tyrosine kinase 2 (TYK2) is primarily involved in immune and inflammatory signaling and acts like a molecular “control switch” that regulates inflammatory pathways inside immune cells. We’re driven to advance understanding of the TYK2 pathway to help address the unmet needs of those living with inflammatory diseases, like #psoriasis and #PsoriaticArthritis. Hear more about the TYK2 pathway from Andy Plump of Research & Development at Takeda.
-
You wouldn’t navigate a new city without a map. Why should molecular discovery be any different? For Schrödinger’s Mayank Misra, the Schrödinger equation is the ultimate GPS for the atomic scale. The equation tells us where the electrons are, and that knowledge changes everything. But beyond the data, there’s a deeper realization: The universe is inherently full of randomness. For Mayank, that's not a challenge to be solved, it’s a liberating truth. #Schrodinger100Years
-
Schrödinger employees, Magdalene Romero and Erica Del Monaco, attended NVIDIA GTC, where NVIDIA CEO Jensen Huang and other industry leaders spoke about the next frontiers of AI innovation and technologies reshaping the world. Our participation included a panel featuring Schrödinger's Shane Brauner as well as Perry Nightingale, Jason Monden, and Sony Mohapatra. Panelists revealed insights on building production-grade AI stacks. Shane shared how we use Google Cloud Services to accelerate the discovery of novel therapeutics and materials. We are grateful for the opportunity to share our work alongside the brightest minds in the industry! #GTC2026